Cytokines in the Management of Leishmaniasis

Badaró, Roberto; Carvalho, Jeferson Silva; Badaro, F.; Nascimento, Cristiana; Sobel, Jeremy; Saito, Yuri; Johnson, Warren D.; Jones, Thomas C.

doi:10.1159/000422236

Cited by 5 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The former treatment had considerably fewer and milder side effects. The inclusion of macrophage activating cytokines in the treatment of antimony resistant VL initially gave promissing results, but high frequencies of relapses (Badaro et al 1993) suggest that these patients often lack fundamental defence mechanisms against leishmaniaisis. Thus a short term macrophage activation may apparently cure the disease but it cannot restore basic defence deficiencies.…”

Section: Regulator a N D Effector Functions Of T-cell Subsets In H U mentioning

confidence: 99%

Regulator and effector functions of T‐cell subsets in human Leishmanaia infections

Kemp

1997

APMIS

View full text Add to dashboard Cite

Section: Regulator a N D Effector Functions Of T-cell Subsets In H U mentioning

confidence: 99%

Regulator and effector functions of T‐cell subsets in human Leishmanaia infections

Kemp

1997

APMIS

View full text Add to dashboard Cite

“…Of particular interest is the apparent isotype switching seen in sera from patient no. 8, who was previously treated for DCL (1,2). This was the only serum specimen with a predominant IgG2 subclass specificity (absorbance, 1.44) toward hsp83.…”

mentioning

confidence: 98%

“…Sera from all 10 DCL patients analyzed were positive with the lysate, and seven specimens had absorbance values of Ͼ2. The lowest titer was for a sample from a donor who had undergone cytokine therapy (1,2). The sera were further examined to determine their IgG subclass (IgG1, IgG2, IgG3, and IgG4) specificities.…”

mentioning

confidence: 99%

Association of Leishmania heat shock protein 83 antigen and immunoglobulin G4 antibody titers in Brazilian patients with diffuse cutaneous leishmaniasis

et al. 1997

View full text Add to dashboard Cite

Diffuse cutaneous leishmaniasis (DCL) is characterized by the presence of numerous nonulcerated nodules and plaques containing large numbers of Leishmania amazonensis parasites and few lymphoid elements. The immune responses of DCL patients reflect severe antigen-specific T-cell deficiencies, while the antibody response to Leishmania antigens is often accentuated. We report herein on the Leishmania antigen-specific antibody subclass distribution in DCL patients and demonstrate that a dominant antigen contributing to the biased immunoglobulin G4 antibody subclass in sera of DCL patients is Leishmania heat shock protein 83.

show abstract

“…In a prospective study, bacterial nosocomial infection occurred in 14 of 18 (77%) patients with neutrophils (PMN) < 1500/mm 3 [149] while 6 of 12 developed bacterial infections with PMN > 1500/ram 3. This led us to evaluate the potential benefits of recombinant GM-CSF and document safety [150]. We studied the effect of GM-CSF in combination with one-half of the usual dose of Sb 5 against full dose Sb 5 in 20 VL patients (Badaro R, Reed S, Ho JL, et aL [151]).…”

Section: Ifn-~/and DCLmentioning

confidence: 99%

Cytokines in the treatment of leishmaniasis: From studies of immunopathology to patient therapy

Badaró

Hatzigeorgiou

et al. 1994

Biotherapy

Self Cite

View full text Add to dashboard Cite

The genus Leishmania, an obligate intramacrophage parasite, causes a wide spectrum of clinical diseases. It is worldwide in distribution and causes 20 million new cases annually with an at risk population of approximately 1.5 billion persons. The most severe forms are associated with high morbidity, mortality and relapses with conventional therapy. The therapeutic issues and responses to standard and alternative therapies are reviewed. Recent developments in molecular biology and immunology methods employed in the study of leishmaniasis have defined an intricate interaction of the parasite with host immune system. Perturbation of the host immune responses may be part of the survival mechanisms of Leishmania. In murine model, the finding of T helper cells that differ by their panel of cytokines has allowed a more precise definition of immunopathogenesis of leishmaniasis. Preliminary data from leishmaniasis patients lend support to this concept of altered immunomodulation. Furthermore, the data from leishmaniasis patients lend support to this concept of altered enhancement of therapeutic response by interferon-gamma has provided a new approach for treatment of patients using recombinant cytokines and for the study of the disease. Current research for early diagnosis, alternative therapies and need for vaccines are reviewed in the context of the immunopathology of leishmaniasis.

show abstract

Cytokines in the Management of Leishmaniasis

Cited by 5 publications

References 0 publications

Regulator and effector functions of T‐cell subsets in human Leishmanaia infections

Regulator and effector functions of T‐cell subsets in human Leishmanaia infections

Association of Leishmania heat shock protein 83 antigen and immunoglobulin G4 antibody titers in Brazilian patients with diffuse cutaneous leishmaniasis

Cytokines in the treatment of leishmaniasis: From studies of immunopathology to patient therapy

Contact Info

Product

Resources

About